Symptomatic vitreomacular adhesion treatment accepted for review by EMA

Article

Ocriplasmin, a treatment for symptomatic vitreomacular adhesion, has been accepted for review by the European Medicines Agency (EMA).

Ocriplasmin, a treatment for symptomatic vitreomacular adhesion, has been accepted for review by the European Medicines Agency (EMA).

The 2.5 mg/mL solution for injection, developed by ThromboGenics (Leuven, Belgium), prevents retinal distortion and further decreases in vision in VMA patients including macular hole. If ocriplasmin is approved it will be the first pharmacological treatment for VMA including macular hole. The solution will be available in the EU and the US.

The CEO of ThromboGenics, Dr Patrik De Haes, said, “The global ThromboGenics team is proud to have achieved the successful acceptance for review of the European MAA for ocriplasmin, a major corporate milestone. Ocriplasmin is also expected to be filed with the FDA in the US by the end of the year. If approved, ocriplasmin will be the first pharmacological treatment for a condition that is currently only treated via surgery, and only after the patient’s vision has significantly deteriorated."

ThromboGenics completed two Phase II clinical trials for ocrimplasmin. The drug is currently in clinical trials for further vitreoretinal conditions. Dr De Haes said, “We are continuing to make excellent progress in building our commercial organization to educate and support the retina specialist community, with the aim of ensuring ocriplasmin achieves its full therapeutic potential and delivers maximum benefit to patients.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.